ACADIA Pharmaceuticals Inc (NASDAQ:ACAD)
| 20.82 Delayed Data As of Sep 29 |  -0.71 / -3.30%Today’s Change | 13.73 Today|||52-Week Range 33.99 | +30.78% Year-to-Date |
Latest ACAD News | Press Releases
| 2 Growth Stocks I'd Buy on the Dip Sep 30 / MotleyFool.com - Paid Partner Content | Acadia (ACAD) Surges 8.3%: Is This an Indication of Further Gains? Sep 28 / Zacks.com - Paid Partner Content |
Today’s Trading
| Previous close | 21.53 |
| Today’s open | 21.45 |
| Day’s range | 20.54 - 21.45 |
| Volume | 197,465 |
| Average volume (3 months) | 1,684,328 |
| Market cap | $3.4B |
Data as of 4:00pm ET, 09/29/2023
Growth & Valuation
| Earnings growth (last year) | -27.71% |
| Earnings growth (this year) | +76.75% |
| Earnings growth (next 5 years) | -2.00% |
| Revenue growth (last year) | +6.83% |
| P/E ratio | NM |
| Price/Sales | 4.98 |
| Price/Book | 8.43 |
Competitors
| Today’s change | Today’s % change | |
|---|---|---|
| FOLDAmicus Therapeutics ... | +0.29 | +2.45% |
| EVOEvotec SE | +0.20 | +2.05% |
| ---- | ||
| KRYSKrystal Biotech Inc | -1.80 | -1.53% |
Data as of 4:00pm ET, 09/29/2023
Financials
| Next reporting date | November 6, 2023 |
| EPS forecast (this quarter) | -$0.17 |
| Annual revenue (last year) | $517.2M |
| Annual profit (last year) | -$216.0M |
| Net profit margin | -41.76% |
Profile
Sector Health Technology |
Industry Pharmaceuticals: Major |
No executives to display |
Corporate headquarters San Diego, California |
Forecasts
